These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29743548)

  • 1. Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
    Smolarczyk R; Cichoń T; Pilny E; Jarosz-Biej M; Poczkaj A; Kułach N; Szala S
    Sci Rep; 2018 May; 8(1):7355. PubMed ID: 29743548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
    Rauca VF; Patras L; Luput L; Licarete E; Toma VA; Porfire A; Mot AC; Rakosy-Tican E; Sesarman A; Banciu M
    Sci Rep; 2021 Nov; 11(1):22102. PubMed ID: 34764332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells.
    Rauca VF; Licarete E; Luput L; Sesarman A; Patras L; Bulzu P; Rakosy-Tican E; Banciu M
    PLoS One; 2018; 13(8):e0202827. PubMed ID: 30138430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
    Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
    Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.
    Zhang H; Qian DZ; Tan YS; Lee K; Gao P; Ren YR; Rey S; Hammers H; Chang D; Pili R; Dang CV; Liu JO; Semenza GL
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19579-86. PubMed ID: 19020076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent-DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors.
    Drzyzga A; Cichoń T; Czapla J; Jarosz-Biej M; Pilny E; Matuszczak S; Wojcieszek P; Urbaś Z; Smolarczyk R
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
    Downey CM; Aghaei M; Schwendener RA; Jirik FR
    PLoS One; 2014; 9(6):e99988. PubMed ID: 24940883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
    Wang LC; Thomsen L; Sutherland R; Reddy CB; Tijono SM; Chen CJ; Angel CE; Dunbar PR; Ching LM
    Neoplasia; 2009 Aug; 11(8):793-803. PubMed ID: 19649209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digoxin inhibits blood vessel density and HIF-1a expression in castration-resistant C4-2 xenograft prostate tumors.
    Gayed BA; O'Malley KJ; Pilch J; Wang Z
    Clin Transl Sci; 2012 Feb; 5(1):39-42. PubMed ID: 22376255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
    Terzuoli E; Donnini S; Giachetti A; Iñiguez MA; Fresno M; Melillo G; Ziche M
    Clin Cancer Res; 2010 Aug; 16(16):4207-16. PubMed ID: 20682710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
    Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
    Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.
    Jarosz-Biej M; Kamińska N; Matuszczak S; Cichoń T; Pamuła-Piłat J; Czapla J; Smolarczyk R; Skwarzyńska D; Kulik K; Szala S
    PLoS One; 2018; 13(1):e0191012. PubMed ID: 29320562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1α, MMP-2, MMP-9, and VEGF.
    Pratheeshkumar P; Kuttan G
    J Environ Pathol Toxicol Oncol; 2011; 30(2):139-51. PubMed ID: 21967458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
    Wallace A; LaRosa DF; Kapoor V; Sun J; Cheng G; Jassar A; Blouin A; Ching LM; Albelda SM
    Cancer Res; 2007 Jul; 67(14):7011-9. PubMed ID: 17638914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
    J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
    Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.
    Lequeux A; Noman MZ; Xiao M; Van Moer K; Hasmim M; Benoit A; Bosseler M; Viry E; Arakelian T; Berchem G; Chouaib S; Janji B
    Oncogene; 2021 Jul; 40(28):4725-4735. PubMed ID: 34155342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oltipraz and dithiolethione congeners inhibit hypoxia-inducible factor-1alpha activity through p70 ribosomal S6 kinase-1 inhibition and H2O2-scavenging effect.
    Lee WH; Kim YW; Choi JH; Brooks SC; Lee MO; Kim SG
    Mol Cancer Ther; 2009 Oct; 8(10):2791-802. PubMed ID: 19789218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.